Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

Wei Wang, a UH College of Pharmacy research associate professor, is helping to develop a new targeted drug to treat triple-negative breast cancer. Photo courtesy UH.

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”

From Your Site Articles
MD Anderson is teaming up with TOPPAN Holdings on cutting-edge organoid tech to help match cancer patients with the most effective treatments. Photo via Getty Images.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."

Rice University's Lei Li has been awarded a $550,000 NSF CAREER Award to develop wearable, hospital-grade medical imaging technology. Photo by Jeff Fitlow/ Courtesy Rice University

Rice University professor earns $550k NSF award for wearable imaging tech​

science supported

Another Houston scientist has won one of the highly competitive National Science Foundation (NSF) CAREER Awards.

Lei Li, an assistant professor of electrical and computer engineering at Rice University, has received a $550,000, five-year grant to develop wearable, hospital-grade medical imaging technology capable of visualizing deep tissue function in real-time, according to the NSF. The CAREER grants are given to "early career faculty members who demonstrate the potential to serve as academic models and leaders in research and education."

“This is about giving people access to powerful diagnostic tools that were once confined to hospitals,” Li said in a news release from Rice. “If we can make imaging affordable, wearable and continuous, we can catch disease earlier and treat it more effectively.”

Li’s research focuses on photoacoustic imaging, which merges light and sound to produce high-resolution images of structures deep inside the body. It relies on pulses of laser light that are absorbed by tissue, leading to a rapid temperature rise. During this process, the heat causes the tissue to expand by a fraction, generating ultrasound waves that travel back to the surface and are detected and converted into an image. The process is known to yield more detailed images without dyes or contrast agents used in some traditional ultrasounds.

However, current photoacoustic systems tend to use a variety of sensors, making them bulky, expensive and impractical. Li and his team are taking a different approach.

Instead of using hundreds of separate sensors, Li and his researchers are developing a method that allows a single sensor to capture the same information via a specially designed encoder. The encoder assigns a unique spatiotemporal signature to each incoming sound wave. A reconstruction algorithm then interprets and decodes the signals.

These advances have the potential to lower the size, cost and power consumption of imaging systems. The researchers believe the device could be used in telemedicine, remote diagnostics and real-time disease monitoring. Li’s lab will also collaborate with clinicians to explore how the miniaturized technology could help monitor cancer treatment and other conditions.

“Reducing the number of detection channels from hundreds to one could shrink these devices from bench-top systems into compact, energy-efficient wearables,” Li said in the release. “That opens the door to continuous health monitoring in daily life—not just in hospitals.”

Amanda Marciel, the William Marsh Rice Trustee Chair of chemical and biomolecular engineering and an assistant professor at Rice, received an NSF CAREER Award last year. Read more here.

The Rice Biotech Launch Pad has named two bioengineering professors to its leadership team. Photo courtesy Rice University.

Rice biotech accelerator appoints 2 leading researchers to team

Launch Pad

The Rice Biotech Launch Pad, which is focused on expediting the translation of Rice University’s health and medical technology discoveries into cures, has named Amanda Nash and Kelsey L. Swingle to its leadership team.

Both are assistant professors in Rice’s Department of Bioengineering and will bring “valuable perspective” to the Houston-based accelerator, according to Rice.

“Their deep understanding of both the scientific rigor required for successful innovation and the commercial strategies necessary to bring these technologies to market will be invaluable as we continue to build our portfolio of lifesaving medical technologies,” Omid Veiseh, faculty director of the Launch Pad, said in a news release.

Amanda Nash

Nash leads a research program focused on developing cell communication technologies to treat cancer, autoimmune diseases and aging. She previously trained as a management consultant at McKinsey & Co., where she specialized in business development, portfolio strategy and operational excellence for pharmaceutical and medtech companies. She earned her doctorate in bioengineering from Rice and helped develop implantable cytokine factories for the treatment of ovarian cancer. She holds a bachelor’s degree in biomedical engineering from the University of Houston.

“Returning to Rice represents a full-circle moment in my career, from conducting my doctoral research here to gaining strategic insights at McKinsey and now bringing that combined perspective back to advance Houston’s biotech ecosystem,” Nash said in the release. “The Launch Pad represents exactly the kind of translational bridge our industry needs. I look forward to helping researchers navigate the complex path from discovery to commercialization.”

Kelsey L. Swingle

Swingle’s research focuses on engineering lipid-based nanoparticle technologies for drug delivery to reproductive tissues, which includes the placenta. She completed her doctorate in bioengineering at the University of Pennsylvania, where she developed novel mRNA lipid nanoparticles for the treatment of preeclampsia. She received her bachelor’s degree in biomedical engineering from Case Western Reserve University and is a National Science Foundation Graduate Research Fellow.

“What draws me to the Rice Biotech Launch Pad is its commitment to addressing the most pressing unmet medical needs,” Swingle added in the release. “My research in women’s health has shown me how innovation at the intersection of biomaterials and medicine can tackle challenges that have been overlooked for far too long. I am thrilled to join a team that shares this vision of designing cutting-edge technologies to create meaningful impact for underserved patient populations.”

The Rice Biotech Launch Pad opened in 2023. It held the official launch and lab opening of RBL LLC, a biotech venture creation studio in May. Read more here.

Sentinel BioTherapeutics is developing cytokine interleukin-2 (IL-2) capsules to fight many solid tumors. Photo via Getty Images.

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

A team of researchers at the University of Houston is working to develop a new treatment for Rhabdomyosarcoma, an aggressive cancer with a higher incidence in young children. Photo via Getty Images.

UH research team receives grant to fight aggressive pediatric cancer

cancer research

Researchers at the University of Houston have received a $3.2 million grant from the National Institutes of Health to help find innovative ways to treat Rhabdomyosarcoma, or RMS.

According to a statement from the university, RMS is a malignant soft tissue sarcoma that has a higher incidence in young children and is responsible for 8 percent of pediatric cancer cases with a relatively low survival rate.

One way UH is working on the issue is by studying how and why RMS cells, which are found most often in muscle tissue, divide uncontrollably without ever maturing into normal muscle cells. The researchers aim to tackle a target inside RMS cells known as TAK1, which plays a key role in regulating cell growth.

“By targeting TAK1, we aim to stop the cancer at its source and help the cells develop normally,” Ashok Kumar, the Else and Philip Hargrove Endowed Professor of Drug Discovery at the UH College of Pharmacy and director of the Institute of Muscle Biology and Cachexia, said in a news release. “This approach could lead to new and better treatments for RMS.”

According to UH, preliminary results demonstrated that TAK1 is highly activated in embryonal RMS cells, which are found in younger children; alveolar RMS cells, which are found in older children and teens; and human RMS samples. This suggests that the protein plays a major role in the development of this form of cancer.

The team still aims to uncover how the protein helps RMS cancer grow and plans to evaluate how blocking TAK1 can be used as a therapeutic.

“Blocking TAK1, either by changing the genes (genetic approaches) or using drugs (pharmacological approaches), can stop certain harmful behaviors in cancer cells,” Kumar added. “This was tested both in lab-grown cells and in living models, showing that TAK1 is a key target to control RMS cancer’s spread and aggressiveness, and inhibits tumor formation.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

UH breakthrough moves superconductivity closer to real-world use

Energy Breakthrough

University of Houston researchers have set a new benchmark in the field of superconductivity.

Researchers from the UH physics department and the Texas Center for Superconductivity (TcSUH) have broken the transition temperature record for superconductivity at ambient pressure. The accomplishment could lead to more efficient ways to generate, transmit and store energy, which researchers believe could improve power grids, medical technologies and energy systems by enabling electricity to flow without resistance, according to a release from UH.

To break the record, UH researchers achieved a transition temperature 151 Kelvin, which is the highest ever recorded at ambient pressure since the discovery of superconductivity in 1911.

The transition temperature represents the point just before a material becomes superconducting, where electricity can flow through it without resistance. Scientists have been working for decades to push transition temperature closer to room temperature, which would make superconducting technologies more practical and affordable.

Currently, most superconductors must be cooled to extremely low temperatures, making them more expensive and difficult to operate.

UH physicists Ching-Wu Chu and Liangzi Deng published the research in the Proceedings of the National Academy of Sciences earlier this month. It was funded by Intellectual Ventures and the state of Texas via TcSUH and other foundations. Chu, founding director and chief scientist at TcSUH, previously made the breakthrough discovery that the material YBCO reaches superconductivity at minus 93 K in 1987. This helped begin a global competition to develop high-temperature superconductors.

“Transmitting electricity in the grid loses about 8% of the electricity,” Chu, who’s also a professor of physics at UH and the paper’s senior author, said in a news release. “If we conserve that energy, that’s billions of dollars of savings and it also saves us lots of effort and reduces environmental impacts.”

Chu and his team used a technique known as pressure quenching, which has been adapted from techniques used to create diamonds. With pressure quenching, researchers first apply intense pressure to the material to enhance its superconducting properties and raise its transition temperature.

Next, researchers are targeting ambient-pressure, room-temperature superconductivity of around 300 K. In a companion PNAS paper, Chu and Deng point to pressure quenching as a promising approach to help bridge the gap between current results and that goal.

“Room-temperature superconductivity has been seen as a ‘holy grail’ by scientists for over a century,” Rohit Prasankumar, director of superconductivity research at Intellectual Ventures, said in the release. “The UH team’s result shows that this goal is closer than ever before. However, the distance between the new record set in this study and room temperature is still about 140 C. Closing this gap will require concerted, intentional efforts by the broader scientific community, including materials scientists, chemists, and engineers, as well as physicists.”

---

This article originally appeared on EnergyCapitalHTX.com.

Rice University to lead AI conferences in Paris this spring and summer

where to be

Houston’s own Rice University will host a series of conferences on artificial intelligence in Paris, France, starting this month. The series will tackle the impact and possibilities of AI in fields like econometrics and online privacy security.

“Artificial intelligence is transforming the global economy and raising profound questions about how technology intersects with society,” Caroline Levander, Rice’s vice president for global strategy, said in a news release. “By convening scholars from multiple disciplines and countries in Paris, Rice is helping shape the international conversation about how AI should be developed, governed and used.”

The four conferences in Paris aim for a multi-disciplinary approach that tackles aspects of AI from diverging angles. The conferences come as part of Rice’s increased partnership with French researchers at the Université Paris Sciences & Lettres. The two institutions have formed a binary star system of academic sharing and support.

“Paris has quickly become one of the most important global hubs for artificial intelligence research, entrepreneurship and policy,” Levander said. “For Rice, having a presence in the city allows our scholars to engage directly with that ecosystem while building collaborations that connect Europe and the United States around the future of AI.”

The conferences will be held at the Rice Global Paris Center. Topics scheduled are:

Emerging Topics in Operations Management: Platforms, Blockchains and AI

April 27-29

This conference will focus on how companies like Uber, Airbnb, Spotify, and DoorDash can use blockchain ledgers to deliver goods and services more transparently. It will also look at tokenized incentives, presumably forms of cryptocurrency and non-fungible tokens in the app space.

Econometrics and AI

May 5-7

This conference will explore how AI can be used in various economic statistical models and practices.

Human Flourishing in the Age of AI

June 3-5

This conference will be a collaboration between engineers and philosophers about the ethics and impact of AI on the lives of its users.

On the Crossroads of AI and Society: Incentives, Privacy and Fairness

July 15-16

This conference will consider how to stakeholders can ensure AI’s actions most benefit people, particularly in the fields of healthcare education, energy and public policy.

Houston claims 19% of Texas’ new live-work-play growth

by the numbers

In Texas, Houston is a big player in the live-work-play real estate movement.

A new 21-city analysis from coworking marketplace CoworkingCafe shows the Houston area added five live-work-play projects—mixed-use developments with residential, office and recreational components—over the past decade.

From 2016 to 2025, Houston accounted for 19 percent of Texas’ new live-work-play inventory, the analysis shows. Among the new local developments were Arrive Upper Kirby, St. Andrie, and The Laura:

  • Arrive Upper Kirby, which was sold in 2021 for $182 million, offers more than 61,000 square feet of retail and restaurant space adjacent to apartments and offices. The 13-story, 265,000-square-foot project was completed in 2017.
  • St. Andrie, a 32-acre, mixed-use community, was completed in 2019. The apartment-anchored development includes an H-E-B grocery store and 37,000 square feet of office space.
  • The Laura, spanning 110,000 square feet, was completed in 2023. Among the apartment complex’s amenities is a coworking space.

According to Northspyre, a software provider for real estate developers, live-work-play projects enable people to meet their needs, such as housing, workplaces, stores, restaurants, and recreation facilities, in a single place.

A total of 542 live-work-play developments opened between 2016 and 2025 in the 21 cities, with another 69 in the pipeline for 2026, CoworkingCafe says. Among major markets, New York City made up the largest share (119) of new live-work-play developments from 2016 to 2025.

The Houston area’s five projects were built in 2018, 2019, 2020, 2024, and 2025, CoworkingCafe data indicates, with another project scheduled for completion next year. The Greater Houston Partnership recently highlighted four mixed-use projects taking shape in the region, but only one of them is scheduled to be finished in 2027. It can take two to five years or more to complete a mixed-use development.

Of the five Houston developments finished in the past decade, 56 percent of the space went toward multifamily units, 29 percent toward offices, and 16 percent toward retail, CoworkingCafe says.

As noted by the Houston-Galveston Area Council, economic development in the 21st century “is about cultivating quality live-work-play environments that attract, retain, and grow a diverse and skilled population. Employers and businesses are increasingly choosing to make long-term investments in places that connect and engage people to strengthen economic competitiveness and promote innovation.”

With eight completed projects, Austin led construction of live-work-play developments in Texas from 2016 to 2025, according to CoworkingCafe. Dallas, which welcomed five live-work-play developments during that period, tied with Houston. San Antonio data wasn’t available.

View All Listings